SCHEMBL20556

SCHEMBL20556

COc1cc(Nc2nc3c(-c4ccc(OC)nc4)nccn3n2)cc(OC)c1

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 14/20 0.50
PTK2 Q05397 10/20 0.50
JAK3 P52333 5/20 0.47
CDK2 P24941 1/20 0.43
GSK3B P49841 1/20 0.43
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
FYN P06241 1/20 0.40
SYK P43405 2/20 0.39
EIF2AK4 Q9P2K8 1/20 0.39
SRC P12931 1/20 0.38
ZAP70 P43403 1/20 0.38
EGFR P00533 1/20 0.38
FGFR1 P11362 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21119 0.91 JAK2 (0.52) JAK2PTK2JAK3
SCHEMBL15207893 0.89 SYK (0.43) JAK2PTK2JAK3CDK2GSK3B
SCHEMBL15208123 0.89 JAK2 (0.41) JAK2PTK2JAK3CDK2GSK3B
SCHEMBL19086 0.88 JAK2 (0.47) JAK2PTK2JAK3FLT1FLT4
SCHEMBL21599 0.87 APP (0.40) JAK2PTK2JAK3CDK2GSK3B
SCHEMBL21584 0.87 FLT1 (0.44) JAK2PTK2JAK3FLT1FLT4
SCHEMBL20859 0.86 JAK2 (0.48) JAK2PTK2JAK3CDK2GSK3B
SCHEMBL15207034 0.86 JAK2 (0.40) JAK2PTK2JAK3FLT1FLT4
SCHEMBL15207207 0.86 FLT1 (0.45) JAK2PTK2JAK3CDK2GSK3B
SCHEMBL15207801 0.86 JAK2 (0.48) JAK2PTK2JAK3SYKEIF2AK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609098-A1 TRIAZOLOPYRAZINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025186-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 JAK2 5/4885PTK2 367/4885JAK3 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.